Oxymetazoline Hydrochloride Catalog No.:M10842-10 wtRyR1-HEK 293 pretreated with KB-R7943

wtRyR1-HEK 293 pretreated with KB-R7943 (10 μM

PA-824 was tested in vitro against a broad panel of multidrug-resistant clinical isolates and was found to be highly active against all isolates (MIC<1 microg/ml)

InChi: InChI=1S/C28H40BrN7O4/c1-16(2)35(12-6-11-31-27(39)34-18-9-7-17(8-10-18)28(3

Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation

Z-VAD-FMK is a cell-permeable

Oxymetazoline Hydrochloride Catalog No.:M10842-10 wtRyR1-HEK 293 pretreated with KB-R7943Oxymetazoline is a selective 1 adrenergic receptor agonist and 2 adrenergic receptor partial agonist. It is a topical decongestant, used in the form of oxymetazoline hydrochloride in products such as Afrin, Dristan, Nasivin, Nezeril, Nostrilla, Logicin, Vicks Sinex, Visine L. R., Sudafed OM, Zicam, SinuFrin and Mucinex Sinus Max. It was developed from xylometazoline at E. Merck Darmstadt by Fruhstorfer in 1961. Oxymetazoline is generally available as